文献速递淋巴瘤

99例原发性肠道淋巴瘤的临床特征、诊断、治疗与预后

[Clinical features, diagnosis, treatment, and prognosis of 99 cases with primary intestinal lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

回顾性分析北京大学肿瘤医院1995年11月1日至2013年11月30日确诊的99例原发性肠道淋巴瘤患者资料,男65例、女34例,中位年龄50岁,腹痛最常见(67例,67.68%),回肠与回盲部原发各21例,弥漫大B细胞淋巴瘤55例(55.56%),中位总生存100.0个月、5年总生存率53.50%,T细胞来源为预后不良独立影响因素。

要点

  • 原发性肠道淋巴瘤好发于男性,腹痛为最常见表现(67.68%),回肠与回盲部为最常见原发部位(各21例)。
  • 消化内镜活检确诊率仅24.24%,69例(69.70%)依靠手术诊断,弥漫大B细胞淋巴瘤占55.56%。
  • 中位总生存100.0个月、5年总生存率53.50%;T细胞来源为独立不良预后因素(P<0.05)。

核心结论

  • 原发性肠道淋巴瘤好发于男性,腹痛最常见,回肠与回盲部为最常见发病部位,内镜确诊率低,弥漫大B细胞淋巴瘤为最常见病理类型,T细胞来源为预后不良的独立影响因素。

研究设计与样本

  • 回顾性分析1995年11月1日至2013年11月30日在北京大学肿瘤医院确诊的99例原发性肠道淋巴瘤患者资料。

主要发现

  • 男65例、女34例(男女比1.9∶1),中位年龄50(12~90)岁;腹痛67例(67.68%),急腹症26例(26.26%)。
  • 回肠原发与回盲部原发均为21例;消化内镜活检确诊24例(24.24%),手术诊断69例(69.70%)。
  • Ⅰ~Ⅱ期71例(71.72%),Ⅳ期28例(28.28%);均为非霍奇金淋巴瘤,B细胞来源77例(77.78%),T细胞来源22例(22.22%),弥漫大B细胞淋巴瘤55例(55.56%),IPI评分0~1分60例。
  • 中位总生存100.0个月,5年总生存率53.50%;多因素分析显示T细胞来源者预后差(P<0.05)。
  • 74例接受手术治疗、96例接受全身化疗;手术联合化疗组与单纯化疗组中位总生存分别为79.0个月和123.0个月,差异无统计学意义(P=0.616)。

临床怎么用

  • 作者认为手术仍是原发性肠道淋巴瘤常用的诊断及治疗手段,且手术并未增加患者的生存风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical features, diagnosis, treatment and prognosis of primary intestinal lymphoma (PIL) . Methods: The characteristics, diagnosis, treatment methods, and follow-up outcomes of 99 PIL patients, diagnosed in Peking university cancer hospital between Nov.1,1995 and Nov. 30, 2013. Results: There were 65 males and 34 females with a median age of 50 years. The majority of clinical manifestation were non-specific gastrointestinal symptoms, 67.68% of cases presented abdominal pain, 26.26% with acute abdomen. The most common primary sites of ileum and ileocecus were identified in 21 cases, respectively. The positive rate of endoscopic was only 24.24%, and 69 cases were diagnosed by operation. 71 patients (71.72%) were stageⅠ-Ⅱand 28 patients (28.28%) were stage Ⅳ. Hodgkin's lymphoma was not found in all patients. Of the 99 cases, 77 were B-cell origin (77.78%) and 22 were T-cell origin. 55 cases (55.56%) were diagnosed with diffuse large B cell lymphoma (DLBCL) . 60 cases presented IPI score 0-1 point. The median overall survival (OS) was 100.0 months, and 5 year overall survival (5y-OS) was 53.5%. By multiple-factors analysis, T-cell origin lymphoma was significantly correlated with poor prognosis (P<0.05) . There was no difference of the median OS between the patients with operation and chemotherapy alone (79.0 vs 123.0 months, P=0.616) . Conclusion: PIL is commonly seen in males. Abdominal pain is the most common clinical manifestations and the most primary sites are ileum and ileocecus. The diagnosis value of the endoscopic is limited. DLBCL is the most common pathologic type of PIL. T-cell origin lymphoma is an independent prognostic factor for PIL. Surgery is still commonly used in the diagnosis and treatment of PIL, and the operation do not increase the risk of death of patients with PIL. 目的:探讨原发肠道恶性淋巴瘤(PIL)的临床特征、诊治方法和预后。方法:回顾性分析1995年11月1日至2013年11月30日在北京大学肿瘤医院确诊的PIL患者病例资料。结果:符合诊断条件的PIL患者99例,男65例,女34例,男女比为1.9∶1,中位年龄50(12~90)岁。胃肠道非特异性症状为主要临床表现,其中腹痛67例(67.68%),最为常见,26例(26.26%)患者发病时伴随有急腹症。回肠原发和回盲部原发均为21例,是最常见的发病部位。经消化内镜活检后诊断的PIL仅24例(24.24%),依靠手术诊断的患者为69例(69.70%)。Ⅰ~Ⅱ期71例(71.72%),Ⅳ期28例(28.28%)。所有病例均为非霍奇金淋巴瘤,B细胞来源77例(77.78%),T细胞来源22例(22.22%)。其中最常见为弥漫大B细胞淋巴瘤(DLBCL),共55例(55.56%);国际预后指数(IPI)评分0~1分60例。本组患者中位总生存(OS)期为100.0个月,5年OS率为53.50%。多因素分析显示,T细胞来源者预后差(P<0.05)。74例患者进行了手术治疗,96例患者进行了全身化疗。手术联合化疗组和单纯化疗组的中位OS期分别为79.0个月和123.0个月,差异无统计学意义(P=0.616)。结论: PIL好发于男性,腹痛是其最常见的临床表现,回肠及回盲部为最常见的发病部位,相对来说PIL发病比较局限,但内镜检查确诊率低下;最常见的病理类型是DLBCL,T细胞来源是PIL预后不良的独立影响因素。手术仍然是PIL常用的诊断及治疗手段,且手术并未增加PIL患者的生存风险。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ping LY, Song YQ, Zheng W, et al. [Clinical features, diagnosis, treatment, and prognosis of 99 cases with primary intestinal lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28395448. doi:10.3760/cma.j.issn.0253-2727.2017.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。